Thanks for emailing that article!
San Francisco, CA, March 10, 2014 — Yehia Hashad, MD, the Vice President and Global Head of Ophthalmology Therapeutic Areas for Allergan, Inc., has joined the Board of Directors of Glaucoma Research Foundation in San Francisco.
“Yehia Hashad has close to twenty years of experience in international clinical drug development and much of his career has been devoted to exploring better treatments for patients,” said Andrew G. Iwach, MD, Chair of the Glaucoma Research Foundation Board of Directors. “Yehia’s global perspective and experience will be a great asset to the Foundation.”
Dr. Hashad’s involvement in ophthalmology as a business leader with degrees in ophthalmology and business have given him substantial exposure and knowledge of market dynamics, policies, and politics, related to drug development in particular.
He is experienced in establishing and retaining clinical/regulatory teams, designing clinical development programs, working with worldwide health authorities, exploring new indications and opportunities for products, and worldwide clinical support of new products. At Allergan he is responsible for creating worldwide therapeutic area strategies, as well as design and oversight of all clinical development programs in ophthalmology therapeutic areas.
“Yehia’s expertise in developing new therapies in the area of clinical ophthalmology will be a welcome addition to our Board of Directors,” said Thomas M. Brunner, President and CEO of the Glaucoma Research Foundation. “In addition, Allergan's ongoing support of our patient education programs has helped countless glaucoma patients for many years.”
Located in San Francisco, the Glaucoma Research Foundation is the nation’s most experienced foundation dedicated solely to glaucoma research and education. In addition to funding innovative research like the Catalyst for a Cure research consortium and the Shaffer Grants for Innovative Glaucoma Research, GRF provides free educational material including the definitive reference for newly diagnosed patients, “Understanding and Living with Glaucoma,” brochures serving those at highest risk including African Americans and Latinos, and the comprehensive glaucoma.org website that answers patients’ questions about glaucoma.
Contact: Andrew Jackson, Director of Communications. Phone: (415) 986-3162.
Last reviewed on October 29, 2017